SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: Poor Man -, buythebuy
Search This Board:
Last Post: 10/25/2016 9:10:21 PM - Followers: 186 - Board type: Free - Posts Today: 0


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Statement of Ownership (sc 13g) 09/29/2016 02:37:33 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:08:00 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:05:49 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:04:54 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:03:09 PM
#17831  Sticky Note USRM Kristin Comella video posted 9-26-16. buythebuy 10/16/16 05:46:26 PM
#17810  Sticky Note Judge rules..court taking partial control... Hornet Driver 10/11/16 12:59:13 PM
#17904   Quote - Folding like a cheap suit sold Poor Man - 10/25/16 08:16:50 PM
#17903   Looks to be failing hard here in my EquityElite 10/25/16 11:12:20 AM
#17901   MINI PUMP OVER...LOL !! Hornet Driver 10/25/16 10:32:36 AM
#17900   Lawsuit?? EquityElite 10/25/16 07:36:50 AM
#17899   Real company with real product$$$ slickinvest 10/25/16 07:32:26 AM
#17898   USRM... .0036...Chart...Reversal setting up here... georgie18 10/25/16 04:44:01 AM
#17897   How anyone can think this stock will go mind1 10/24/16 07:57:07 PM
#17896   Typical Suckers' Play Poor Man - 10/24/16 07:15:52 PM
#17895   Is that good? slickinvest 10/24/16 06:26:11 PM
#17894   Up 100% on $15,000 worth of stock LOL. toddski 10/24/16 06:10:43 PM
#17893   My pleasure...if you need any help with it georgie18 10/24/16 03:31:19 PM
#17892   Thank you! buffalo fan 10/24/16 03:23:26 PM
#17891 is the best but its not realtime...there georgie18 10/24/16 03:09:21 PM
#17890   georgie where is the best place to find buffalo fan 10/24/16 03:06:51 PM
#17889   Oversold pincher charts are very effective and pretty reliable... georgie18 10/24/16 02:39:25 PM
#17888   Wow! EquityElite 10/24/16 02:36:40 PM
#17887   Just a convertible debt cycle- Hornet Driver 10/24/16 02:36:28 PM
#17886   USRM... 0049...up here... georgie18 10/24/16 02:35:59 PM
#17885   Are you seeing the swings yet...or perhaps when georgie18 10/24/16 02:34:23 PM
#17884   Go $USRM - nice call lol, hopefully you buffalo fan 10/24/16 02:27:17 PM
#17883   USRM... 0035 X 0042...Beauty bounce... georgie18 10/24/16 02:25:26 PM
#17882   USRM... 0031 X 0032 off 002 bounce... georgie18 10/24/16 02:18:19 PM
#17881   Up 55% weee USRM$$ slickinvest 10/24/16 12:33:46 PM
#17880   Oh gawd...0.00160 ANOTHER ALL TIME LOW ! Hornet Driver 10/24/16 10:06:12 AM
#17879   What's the BiD? EquityElite 10/24/16 10:04:56 AM
#17878   Feeed...has your "friendship" ended with Miguel? Poor Man - 10/23/16 05:08:48 PM
#17877   Hey IS what made you change your sentiment here? EquityElite 10/22/16 07:08:33 PM
#17876   ScAAAAAAAAAAAAAam InvestorStemCell 10/22/16 03:46:09 PM
#17875   What's go on here? EquityElite 10/21/16 06:13:28 PM
#17874   Oh gawd..0.00190 ANOTHER NEW ALL TIME LOW ! Hornet Driver 10/21/16 03:47:31 PM
#17873   Oh, Dios mío, MIGUEL. !!! Poor Man - 10/21/16 01:58:29 PM
#17872   Quote, "Yep, the only way out of this Hornet Driver 10/21/16 11:46:56 AM
#17871   .002 ANOTHER RECORD ALL TIME LOW TODAY ! Hornet Driver 10/21/16 11:31:12 AM
#17870   Tagged at .002 - Total Mess Poor Man - 10/21/16 11:24:08 AM
#17869   RECORD LOW Bid @ .002 now ! Hornet Driver 10/21/16 09:57:33 AM
#17868   How is that possible? Where is investor's advocate EquityElite 10/21/16 07:32:52 AM
#17867   Hellaciously Bad Stock - Correction Poor Man - 10/20/16 11:54:08 PM
#17866   This Stock is Hellaciously Bad!!! Poor Man - 10/20/16 10:38:15 PM
#17865   ScaaaaaAaaaaaaaaaAaaaaaaAaaaam InvestorStemCell 10/20/16 05:32:51 PM
#17864   The bottom is when there is no longer toddski 10/20/16 03:40:37 PM
#17863   Where is the MC bottom? EquityElite 10/20/16 03:12:45 PM
#17862   More high volume TOTAL COLLAPSE Hornet Driver 10/20/16 02:52:35 PM
#17861   The sector is a scam. 99% of the InvestorStemCell 10/19/16 08:26:58 PM
#17860   I totally agree with you. Thanks to the kuhnstefanie 10/19/16 09:04:51 AM
#17859   Paying the Lawyers??? Poor Man - 10/18/16 11:56:55 PM
#17858   Friday is the DEADLINE for USRM to respond Poor Man - 10/18/16 09:46:06 PM
#17857   20 days till Presidential Election H20-Life 10/18/16 07:17:05 PM
#17856   Stroke Symptoms Reversed in Medical Breakthrough Study H20-Life 10/18/16 07:13:08 PM
#17855   ADULT STEM CELL THERAPY AND CATCHING UP TO H20-Life 10/18/16 07:07:26 PM
#17854   Relating to the Regulation of Human Cells, Tissues, H20-Life 10/18/16 07:06:51 PM